IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points [Seeking Alpha]
IGM Biosciences, Inc. (IGMS)
Last igm biosciences, inc. earnings: 3/26 04:05 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
The global lupus market is projected to grow to $6.78 billion by 2032 and the global Rheumatoid Arthritis drugs market size is projected to reach $38.61 billion by 2032. Two ongoing studies, one single-arm and one randomized, using Aplitabart for the treatment of patients with 2nd-line metastatic colorectal cancer, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $24.08 billion by 2028. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » IGM Biosciences, Inc. NASDAQ: IGMS ) has built a substantial pipeline full of a few clinical candidates that have been progressing in the clinic. One such drug would be imvotamab, which is a CD20 X CD3 bispecific T cell engaging antibody being developed for the treatment of patients with autoimmune disorders. It is already advancing two phase 1b studies using this drug to treat patients with severe sys
Show less
Read more
Impact Snapshot
Event Time:
IGMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGMS alerts
High impacting IGM Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IGMS
News
- IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]Yahoo! Finance
- IGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings [Yahoo! Finance]Yahoo! Finance
- IGM Biosciences Insiders Placed Bullish Bets Worth US$992.2k [Yahoo! Finance]Yahoo! Finance
- IGM Biosciences, Inc. (NASDAQ: IGMS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
IGMS
Earnings
- 11/13/23 - Beat
IGMS
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- IGMS's page on the SEC website